Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

3. september 2026 oppdatert av: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Intervensjonell

Registrering (Antatt)

430

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Clinical Trials Information Group Officer
  • Telefonnummer: 86-0311-69085587
  • E-post: ctr-contact@cspc.cn

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
  • 2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:

    1. HER2-negative confirmed by histological or cytological testing;
    2. Pathological report is available to confirm HR status.
  • 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
  • 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  • 5. Has adequate organ and system functions within 7 days prior to the first dose.
  • 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
  • 7. Expected survival ≥ 3 months.

Exclusion Criteria:

  • 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
  • 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
  • 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
  • 4. With a history of other primary malignant tumors within 5 years before administration.
  • 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
  • 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
  • 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
  • 8. Current clinically significant abnormal interstitial lung disease.
  • 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
  • 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
  • 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
  • 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
  • 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
  • 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
  • 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
  • 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
  • 17. Concurrent participation in another interventional clinical study.
  • 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: HB1801
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
Eksperimentell: Docetaxel (Taxotere®)
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free Survival (PFS)
Tidsramme: up to approximately 2 years after the first enrollment
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
up to approximately 2 years after the first enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR) assessed per RECIST v1.1
Tidsramme: up to approximately 2 years after the first enrollment
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
up to approximately 2 years after the first enrollment
Duration of Response (DOR)
Tidsramme: up to approximately 2 years after the first enrollment
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
up to approximately 2 years after the first enrollment
Disease Control Rate (DCR)
Tidsramme: up to approximately 2 years after the first enrollment
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
up to approximately 2 years after the first enrollment
Overall Survival (OS)
Tidsramme: up to approximately 2 years after the first enrollment
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
up to approximately 2 years after the first enrollment
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Tidsramme: up to approximately 2 years after the first enrollment
up to approximately 2 years after the first enrollment
Plasma concentration of docetaxel (free and total)
Tidsramme: After completion of infusion administration on Day 1 of Cycle 1
After completion of infusion administration on Day 1 of Cycle 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. august 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

28. august 2026

Først innsendt som oppfylte QC-kriteriene

3. september 2026

Først lagt ut (Faktiske)

4. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere